Therefore, our study examined whether xyloketal B could improve NAFLD in both in vitro and in vivo models, and we also explored the possible mechanisms of action of xyloketal B, particularly SREBP-1c-mediated pathways. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.